Genomic and Immunologic Correlates of Immunotherapy Response and Resistance via Longitudinal Tumor and Extracellular Vesicle (EV) Analysis
Abstract
Personnel: Dr. Boland (PI) is an expert in two of the FY18 PRCRP Topic Areas melanoma and immunotherapy. Her leadership roles include serving as the Director of the Massachusetts General Hospital (MGH) Melanoma Surgery Program and the Director of the MGH Surgical Oncology Research Laboratories. She is Associate Member of the Broad Institute of MIT and Harvard and an Assistant Professor at Harvard Medical School (HMS).She is firmly committed to a career understanding how to intelligently use a variety of therapies (including targeted therapies, ICI, intra-lesional therapies)with surgery (neoadjuvant or adjuvant) for the highest quality of care for cancer patients. Her goal is to establish clinically-relevant tools to guide clinical decision-making. Dr. Flaherty is the Director of the Termeer Center for Targeted Therapy and Director of Clinical Research at the MGH Cancer Center. He has a track-record of transitioning novel laboratory research into successful clinical trials in melanoma. He has a strong history of mentoring junior faculty with a superb record of success. Career Development: This award will allow the generation of sufficient preliminary data for an NIH R01 type application. The proposal will allow the integration of Dr. Bolands clinical expertise with novel experimental and analytical techniques to address clinically-relevant questions. Background: Immune checkpoint inhibitors (ICI) targeting cytotoxic T-lymphocyte associated antigen 4 (CTLA-4) and programmed death receptor1 (PD-1) and its ligand (PD-L1) have revolutionized cancer therapy across many cancer types. While 40-45 of patients with metastatic melanoma respond to PD-1 blockade13, the majority still succumb due to primary, adaptive, or acquired resistance4. A diverse set of resistance associated alterations (RAAs)have been identified in the clinical and pre-clinical settings, but when multiple RAAs co-exist how these pathways interact has not yet been well characterized.
Document Details
- Document Type
- Technical Report
- Publication Date
- Jun 01, 2021
- Accession Number
- AD1142151
Entities
People
- Genevieve Boland
Organizations
- Massachusetts General Hospital